Open contest
5 companies value 806 bn revenue 240 bn margin 14.7% free cash flow 55 bn avg. score 6.4
NVS holds 35.6% of the group's value, 1.1x the runner-up
| Rank | Ticker | Company | Share | Value | Revenue | Margin | FCF | 5 years | FCF/px | Yield | What it does · why it is here |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NVS | Novartis Switzerland · score 7.2 | 36% | 287 bn | 55 bn | 23.3% | 17 bn | 5.8% | 3.2% | Innovative medicines and advanced therapies, from Switzerland · Leader in innovative therapies with a diversified pipeline | |
| 2 | AZN | AstraZeneca United Kingdom · score 6.5 | 32% | 254 bn | 61 bn | 17.0% | 11 bn | 4.2% | 1.9% | Biopharma in oncology, cardiometabolic and respiratory · One of the global leaders in oncology, with strong growth | |
| 3 | GSK | GSK plc United Kingdom · score 7.4 | 13% | 107 bn | 44 bn | 19.3% | 8.5 bn | 8.0% | 3.2% | Biopharma in vaccines, HIV and respiratory · Leader in vaccines (shingles) and respiratory diseases | |
| 4 | SNY | Sanofi France · score 6.8 | 12% | 97 bn | 51 bn | 8.7% | 13 bn | 13.8% | — | Medicines and vaccines, with Dupixent, from France · Dupixent, one of the world's fastest-growing drugs; strong in vaccines | |
| 5 | TAK | Takeda Pharmaceutical Japan · score 4.1 | 8% | 62 bn | 28 bn | -3.4% | 5.5 bn | 8.8% | 3.2% | Biopharma in gastro, oncology and neuroscience, from Japan · Japan's largest drugmaker; strong in rare diseases |
Other industries in the same sector
- Sector overview
- Large-cap pharmaceuticals 9 companies
- Biotechnology 57 companies
- Lab tools and consumables 37 companies
- Health insurance and services 17 companies
- Medical devices 87 companies
- Specialty pharmaceuticals 77 companies
- Pharmaceutical distribution 7 companies
- Clinical-stage pharmaceuticals 251 companies
- Robotic surgery and advanced medtech 9 companies
- Hospitals 23 companies
- Emerging biotech 5 companies
- Molecular testing and advanced diagnostics 42 companies
and 22 industries more
- Vaccines and mRNA 14 companies
- Clinical-stage biotech 200 companies
- Generics and biosimilars 10 companies
- Animal health 7 companies
- Contract research (CRO) 10 companies
- Consumer health (OTC) 4 companies
- Healthcare software 18 companies
- Rehabilitation and home care 15 companies
- Genomics and sequencing 9 companies
- Structural heart 8 companies
- Ophthalmology 12 companies
- Medical imaging and hospital equipment 16 companies
- Diagnostic labs 6 companies
- Medical and dental supply distribution 3 companies
- Diabetes monitoring 9 companies
- Pharmaceutical royalties 5 companies
- Respiratory and sleep therapy 9 companies
- Orthopedic implants 17 companies
- Dialysis 3 companies
- Telehealth and digital health 12 companies
- Dental 4 companies
- Medical and recreational cannabis 16 companies
What this is. A catalogue, not a guide. Every industry with stocks listed on the NYSE or NASDAQ, the companies contending for its leadership, what each one does according to its own annual report, and the balance sheet it filed with the SEC.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.